NCT07785739

Brief Summary

This prospective observational study aims to evaluate predictors of disease progression in patients with primary membranous nephropathy and to assess the performance of a prognostic nomogram in predicting renal outcomes in the Egyptian population.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
128

participants targeted

Target at P50-P75 for all trials

Timeline
7mo left

Started Aug 2026

Shorter than P25 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress5%
Aug 2026Mar 2027

First Submitted

Initial submission to the registry

August 20, 2026

Completed
Same day until next milestone

Study Start

First participant enrolled

August 20, 2026

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 20, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 25, 2026

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 20, 2027

Expected
Last Updated

August 25, 2026

Status Verified

August 1, 2026

Enrollment Period

Same day

First QC Date

August 20, 2026

Last Update Submit

August 22, 2026

Conditions

Membranous NephropathyKidney DiseasesNephrotic Syndrome

Keywords

Primary membranous nephropathyPrognostic nomogramDisease progressionRenal outcomesAnti-PLA2R

Outcome Measures

Primary Outcomes (1)

  • Performance of the prognostic nomogram in predicting disease progression

    Ability of the prognostic nomogram to predict disease progression in patients with primary membranous nephropathy, assessed by the area under the receiver operating characteristic curve (AUC).

    6 months

Secondary Outcomes (4)

  • Independent clinical and laboratory predictors of disease progression

    6 months

  • Decline in estimated glomerular filtration rate (eGFR)

    6 months

  • Remission status

    6 month

  • Validation of the prognostic nomogram

    6 months

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adults with biopsy-proven primary membranous nephropathy attending the Nephrology Unit, Department of Internal Medicine, Assiut University Hospitals who meet the eligibility criteria.

You may qualify if:

  • Age ≥ 18 years
  • Biopsy-proven primary membranous nephropathy
  • Written informed consent

You may not qualify if:

  • Secondary membranous nephropathy (e.g., lupus nephritis, hepatitis B or C, malignancy, drug-induced)
  • Pregnancy
  • End-stage kidney disease at presentation
  • Refusal to participate

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (3)

  • Krakowska-Jura K, Kler AN, Wajerowska W, Konieczny A, Banasik M. Prognostic Factors of Proteinuria Remission in Primary Membranous Nephropathy. J Clin Med. 2025 Apr 22;14(9):2880. doi: 10.3390/jcm14092880.

    PMID: 40363910BACKGROUND

  • Laurin LP, Helmuth M, Almaani S, Ayoub I, Chen DP, Villegas LA, Nast CC, Robinson BM, Derebail VK, Waldman M, Bomback AS; CureGN Consortium. Risk Factors for Disease Progression for Adults and Children With Membranous Nephropathy in the Cure Glomerulonephropathy Network (CureGN). Kidney Int Rep. 2025 Mar 24;10(6):1917-1928. doi: 10.1016/j.ekir.2025.03.027. eCollection 2025 Jun.

    PMID: 40630289BACKGROUND

  • Ragy O, Abass W, Kanigicherla DAK, Shinkins B, Bestall J, King N, Brenchley P, Smith A, Hamilton P. PLA2R autoantibodies, a multifaceted biomarker in nephrotic syndrome and membranous nephropathy. Nephrol Dial Transplant. 2025 Aug 1;40(8):1458-1469. doi: 10.1093/ndt/gfaf012.

    PMID: 39820570BACKGROUND

MeSH Terms

Conditions

Glomerulonephritis, MembranousNephrotic SyndromeKidney DiseasesDisease Progression

Condition Hierarchy (Ancestors)

GlomerulonephritisNephritisUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesAutoimmune DiseasesImmune System DiseasesNephrosisDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Essam M Abdel Aziz, prof

    Nephrology Unit, Internal Medicine Department, Assiut University Hospitals, Assiut, Egypt

    STUDY CHAIR

Central Study Contacts

Aisha M Elqathafy, resident

CONTACT

01148313428aisha.18313210@med.aun.edu.eg

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
12 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident

Study Record Dates

First Submitted

August 20, 2026

First Posted

August 25, 2026

Study Start

August 20, 2026

Primary Completion

August 20, 2026

Study Completion (Estimated)

March 20, 2027

Last Updated

August 25, 2026

Record last verified: 2026-08